Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.63 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.45 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.42 |
| ▸ | FNTB | P49356 | 2/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564288 | 1.00 | FOLH1 (0.63) | FOLH1ENPEPRIMKLANAALAD2FNTA | |
| SCHEMBL30234159 | 1.00 | FOLH1 (0.63) | FOLH1ENPEPRIMKLANAALAD2FNTA | |
| SCHEMBL30811199 | 1.00 | FOLH1 (0.63) | FOLH1ENPEPRIMKLANAALAD2FNTA | |
| SCHEMBL23857928 | 0.93 | FOLH1 (0.51) | FOLH1FNTAFNTBPGGT1BGSR | |
| SCHEMBL29642982 | 0.93 | FOLH1 (0.51) | FOLH1FNTAFNTBPGGT1BGSR | |
| SCHEMBL30307570 | 0.93 | FOLH1 (0.51) | FOLH1FNTAFNTBPGGT1BGSR | |
| SCHEMBL30307583 | 0.93 | FOLH1 (0.51) | FOLH1FNTAFNTBPGGT1BGSR | |
| SCHEMBL31520392 | 0.93 | FOLH1 (0.51) | FOLH1FNTAFNTBPGGT1BGSR | |
| SCHEMBL30856932 | 0.93 | FOLH1 (0.51) | FOLH1FNTAFNTBPGGT1BGSR | |
| SCHEMBL31679371 | 0.92 | FOLH1 (0.50) | FOLH1FNTAFNTBPGGT1BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098441-A1 | COMPOSITION AND METHOD FOR CANCER TREATMENT USING POLYPEPTIDE CONJUGATES | SUZHOU SMARTNUCLIDE BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-15 | — | — | WO | claimed |
| US-20240327511-A1 | A33 ANTIBODY COMPOSITIONS AND METHODS OF USING THE SAME IN RADIOIMMUNOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-10-03 | — | — | US | claimed |
| US-20240002501-A1 | ANTI-L1-CAM ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-01-04 | — | — | US | claimed |
| US-20230348853-A1 | C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-11-02 | — | — | US | claimed |
| CN-116801889-A | Compositions comprising ex vivo armed T cells with multispecific antibodies and uses thereof | 纪念斯隆凯特琳癌症中心 | 2023-09-22 | — | — | CN | claimed |
| US-20230270857-A1 | COMPOSITIONS INCLUDING EX VIVO ARMED T CELLS WITH MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-08-31 | — | — | US | claimed |
| US-20230235087-A1 | ANTI-GD2 SADA CONJUGATES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-07-27 | — | — | US | claimed |
| CN-116194133-A | anti-GD 2 SADA conjugates and uses thereof | 纪念斯隆凯特琳癌症中心 | 2023-05-30 | — | — | CN | claimed |
| CN-116096433-A | Immune cells expressing C825 and diagnostic uses thereof | 纪念斯隆凯特琳癌症中心 | 2023-05-09 | — | — | CN | claimed |
| EP-4157293-A1 | ANTI-GD2 SADA CONJUGATES AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2023-04-05 | — | — | EP | claimed |
| WO-2026098441-A1 | COMPOSITION AND METHOD FOR CANCER TREATMENT USING POLYPEPTIDE CONJUGATES | SUZHOU SMARTNUCLIDE BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-15 | — | — | WO | disclosed |
| US-12612456-B2 | CD19 antibodies and methods of using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260042860-A1 | ANTI-CD24 ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260015435-A1 | ANTI-POLYSIALIC ACID ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4676599-A1 | IMPROVED BISPECIFIC ANTI-TUMOR ANTIGEN/ANTI-HSG ANTIBODIES FOR PRE-TARGETING OF HYPERPROLIFERATIVE DISORDERS | OncoOne Research & Development GmbH (AT) | 2026-01-14 | — | — | EP | disclosed |
| WO-2022081443-A2 | ANTI-PSMA ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-114341176-A | CD19 antibodies and methods of use thereof | 纪念斯隆凯特琳癌症中心 | 2022-04-12 | — | — | CN | disclosed |
| EP-3976659-A1 | ANTI-GLYPICAN-3 ANTIBODIES AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3953385-A1 | CD19 ANTIBODIES AND METHODS OF USING THE SAME | Memorial Sloan Kettering Cancer Center (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2022026439-A2 | COMPOSITIONS INCLUDING EX VIVO ARMED T CELLS WITH MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042860-A1 | ANTI-CD24 ANTIBODIES AND USES THEREOF | CD22, FCGR2A, CD2BP2 | FOLH1 181/4885ENPEP 336/4885RIMKLA 4461/4885 |
| US-20230348853-A1 | C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF | CD4, LY96, CD81 | FOLH1 185/4885ENPEP 631/4885RIMKLA 4162/4885 |
| US-12612456-B2 | CD19 antibodies and methods of using the same | CD74, CD4, CD2 | FOLH1 569/4885ENPEP 901/4885RIMKLA 4456/4885 |
| US-20260015435-A1 | ANTI-POLYSIALIC ACID ANTIBODIES AND USES THEREOF | VSIG8, CD74, FCGR2A | FOLH1 785/4885ENPEP 2230/4885RIMKLA 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.